|CTI BioPharma Corp.|
3101 Western Avenue
United States - Map
CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
|CTI BioPharma Corp.’s ISS Governance QuickScore as of Aug 1, 2014 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 9; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. James A. Bianco M.D.,
Principal Founder, Chief Exec. Officer, Pres, Exec. Director, Member of Scientific Advisory Board and Member of Exec. Committee
|Dr. Jack W. Singer M.D.,
Co-Founder, Chief Compliance Officer, Interim Chief Medical Officer, Exec. VP of Global Medical Affairs & Translational Medicine, Exec. Director and Member of Scientific Advisory Board
|Mr. Louis A. Bianco CPA,
Co-Founder, Principal Financial Officer, Principal Accounting Officer, Chief Governance Officer, Exec. VP of Fin. & Admin. and Sec.
|Dr. Matthew J. Plunkett Ph.D.,
Exec. VP of Corp. Devel.
|Ms. Monique M. Greer Sr.,
Sr. VP of Corp. Communications and Investor Relations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|